<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2112200352
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALGAN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Valganciclovir
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        450
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2499.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Valganciclovir Tablets 450mg belongs to a group of medicines, which work directly to prevent the growth of viruses. In the body the active ingredient in the tablets, valganciclovir, is changed into ganciclovir. Ganciclovir prevents a virus called cytomegalovirus (CMV) from multiplying and invading healthy cells. In patients with a weakened immune system, CMV can cause an infection in the body&rsquo;s organs. This can be life threatening.</p><p>Valganciclovir Tablets 450mg is used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the treatment of CMV-infections of the retina of the eye in adult patients with acquired immunodeficiency syndrome (AIDS). CMV-infection of the retina of the eye can cause vision problems and even blindness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent CMV-infections in adults and children who are not infected with CMV and who have received an organ transplant from somebody who was infected by CMV.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Valganciclovir Tablets 450mg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to valganciclovir, ganciclovir or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding. Warnings and precautions:</p><p>Talk to your doctor or pharmacist before taking Valganciclovir Tablets 450mg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to aciclovir, penciclovir, valaciclovir or famciclovir. These are other medicines used for viral infections.</p><p>Take special care with Valganciclovir Tablets 450mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low numbers of white blood cells, red blood cells or platelets (small cells involved in blood clotting) in your blood. Your doctor will carry out blood tests before you start taking Valganciclovir Tablets 450mg tablets and more tests will be done while you are taking the tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are having radiotherapy or haemodialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a problem with your kidneys. Your doctor may need to prescribe a reduced dose for you and may need to check your blood frequently during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are currently taking ganciclovir capsules and your doctor wants you to switch to Valganciclovir Tablets 450mg tablets. It is important that you do not take more than the number of tablets prescribed by your doctor or you could risk an overdose.</p><p>Other medicines and Valganciclovir Tablets 450mg</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any&nbsp; other medicines, including medicines obtained without a prescription.</p><p>If you take other medicines at the same time as taking Valganciclovir Tablets 450mg the combination could affect the amount of drug that gets into your blood stream or could cause harmful effects. Tell your doctor if you are already taking medicines that contain any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; imipenem-cilastatin (an antibiotic). Taking this with Valganciclovir Tablets 450mg can cause convulsions (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; zidovudine, didanosine, lamivudine, stavudine, tenofovir, abacavir, emtricitabine or similar kinds of drugs used to treat AIDS</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adefovir or any other medicines used to treat Hepatitis B</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; probenecid (a medicine against gout). Taking probenecid and Valganciclovir Tablets 450mg at the same time could increase the amount of ganciclovir in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mycophenolate mofetil, ciclosporin or tacrolimus (used after transplantations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vincristine, vinblastine, doxorubicin, hydoxyurea or similar kinds of drugs to treat cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trimethoprim, trimethoprim/sulpha combinations and dapsone (antibiotics)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pentamidine (drug to treat parasite or lung infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flucytosine or amphotericin B (anti-fungal agents)</p><p>Valganciclovir Tablets 450mg with food and drink</p><p><strong>&nbsp;</strong></p><p>Valganciclovir Tablets 450mg should be taken with food. If you are unable to eat for any reason, you should still take your dose of Valganciclovir Tablets 450mg as usual.</p><p>Pregnancy, breast-feeding and fertility</p><p><strong>&nbsp;</strong></p><p>You should not take Valganciclovir Tablets 450mg if you are pregnant unless your doctor recommends it. If you are pregnant or planning to become pregnant you must tell your doctor. Taking Valganciclovir Tablets 450mg when you are pregnant could harm your unborn baby. You must not take Valganciclovir Tablets 450mg if you are breast-feeding. If your doctor wants you to begin treatment with Valganciclovir Tablets 450mg you must stop breast-feeding before you start to take your tablets.</p><p>Women of childbearing age must use effective contraception when taking Valganciclovir Tablets 450mg and for at least 30 days after treatment has finished.</p><p>Men whose partners could become pregnant should use condoms while taking Valganciclovir Tablets 450mg and should continue to use condoms for 90 days after treatment has finished.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>Do not drive or use any tools or machines if you feel dizzy, tired, shaky or confused while taking this medicine.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>You have to be careful when handling your tablets. Do not break or crush them. You should swallow them whole and with food whenever possible. If you accidentally touch damaged tablets, wash your hands thoroughly with soap and water. If any powder from the tablets gets in your eyes, rinse your eyes with sterile water or clean water if you do not have sterile water. <strong>You must stick to the number of tablets as instructed by your doctor to avoid overdose.</strong></p><p>Valganciclovir Tablets 450mg tablets should, whenever possible, be taken with food &ndash; see section 2.</p><p>Adults:</p><p><strong>Prevention of CMV disease in transplant patients</strong></p><p>You should start to take this medicine within 10 days of your transplant. The usual dose is two tablets taken ONCE daily. You should continue with this dose for up to 100 days following your transplant. If you have received a kidney transplant, your doctor may advise you to take the tablets for 200 days.</p><p>Treatment of active CMV retinitis in AIDS patients (called induction treatment)</p><p>The usual dose Valganciclovir Tablets 450mg is two tablets taken TWICE a day for 21 days (three weeks). Do not take this dose for more than 21 days unless your doctor tells you to, as this may increase your risk of possible side effects.</p><p>Longer term treatment to prevent recurrence of active inflammation in AIDS patients with CMV retinitis (called maintenance treatment)</p><p>The usual dose is two tablets taken ONCE daily. You should try to take the tablets at the same time each day. Your doctor will advise you how long you should continue to take Valganciclovir Tablets 450mg. If your retinitis worsens while you are on this dose, your doctor may tell you to repeat the induction treatment (as above) or may decide to give you a different medicine to treat the CMV infection.</p><p>&nbsp;</p><p>Elderly patients</p><p>Valganciclovir Tablets 450mg has not been studied in elderly patients.</p><p>Patients with kidney problems</p><p>If your kidneys are not working properly, your doctor may instruct you to take fewer tablets each day or only to take your tablets on certain days each week. It is very important that you only take the number of tablets prescribed by your doctor.</p><p>Patients with liver problems</p><p>Valganciclovir Tablets 450mg has not been studied in patients with liver problems.</p><p>Use in children and adolescents:</p><p><strong>Prevention of CMV disease in transplant patients</strong></p><p>Children should start to take this medicine within 10 days of their transplant. The dose given will vary depending on the size of the child and should be taken ONCE daily. Your doctor will decide the most appropriate dose based on your child&rsquo;s height, weight and renal function. You should continue with this dose for up to 100 days. If your child has received a kidney transplant, your doctor may advise you to take the dose for 200 days.</p><p>For children who are unable to swallow Valganciclovir Tablets 450mg film-coated tables, Valganciclovir Tablets 450mg powder for oral solution can be used.</p><p>If you take more Valganciclovir Tablets 450mg than you should</p><p>Contact your doctor or hospital immediately if you have taken, or think that you have taken, more tablets than you should. Taking too many tablets can cause serious side effects, particularly affecting your blood or kidneys. You may need hospital treatment.</p><p>If you forget to take Valganciclovir Tablets 450mg</p><p>If you forget to take your tablets take the missed dose as soon as you remember and take the next dose at the usual time. Do not take a double dose to make up for the forgotten tablets.</p><p>If you stop taking Valganciclovir Tablets 450mg</p><p>You must not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>. Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions</p><p>&nbsp;</p><p>Up to 1 in every 1,000 people may have a sudden and severe allergic reaction to valganciclovir (anaphylactic shock). STOP taking Valganciclovir Tablets 450mg and go to the accident and emergency department at your nearest hospital if you experience any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a raised, itchy skin rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden swelling of the throat, face, lips and mouth which may cause difficulty swallowing or breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden swelling of the hands, feet or ankles.</p><p>Serious side effects</p><p>Tell your doctor straight away if you notice any of the following serious side effects &ndash; your doctor may tell you to stop taking Valganciclovir Tablets 450mg and you may need urgent medical treatment:</p><p><strong>Very common: </strong>may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell counts &ndash; with signs of infection such as sore throat, mouth ulcers or a fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell counts &ndash; signs include feeling short of breath or tired, palpitations or pale skin</p><p><strong>Common: </strong>may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood infection (sepsis) &ndash; signs include fever, chills, palpitations, confusion and slurred speech</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of platelets &ndash; signs include bleeding or bruising more easily than usual, blood in urine or stools or bleeding from gums, the bleeding could be severe</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely low blood cell count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pancreatitis &ndash; signs are severe stomach pain which spreads into your back</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure of the bone marrow to produce blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations &ndash; hearing or seeing things that are not real</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal thoughts or feelings, losing contact with reality</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure of kidney function</p><p>&nbsp;</p><p>The side effects that have occurred during treatment with valganciclovir or ganciclovir are given below.</p><p>Other side effects</p><p>Tell your doctor, pharmacist or nurse if you notice any of the following side effects: Very common: may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrush and oral thrush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection (e.g. sinusitis, tonsillitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling short of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or being sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eczema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever.</p><p>Common: may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; influenza</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urine infection &ndash; signs include fever, passing urine more often, pain when passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the skin and the tissues under the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mild allergic reaction &ndash; the signs may include red, itchy skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling depressed, anxious or confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hands or feet feeling weak or numb, which may affect your balance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to your sense of touch, tingling, tickling, pricking or burning feeling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to the way things taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye inflammation (conjunctivitis), eye pain or sight problems</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, which may make you feel dizzy or faint</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, wind, indigestion, stomach pain, swelling of the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal results of liver and kidney laboratory tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night sweats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain, muscle or joint pain, muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, weak or generally unwell Uncommon: may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor, shaking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uneven heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives, dry skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infertility in men &ndash; see &lsquo;Fertility&rsquo; section</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>Separation of the inner lining of the eye (detached retina) has only happened in AIDS patients treated with Valganciclovir Tablets 450mg for CMV infection.</p><p>Additional side effects in children and adolescents</p><p>&nbsp;</p><p>The side effects reported in children and adolescents are similar to the side effects reported for adults.</p><p>Reporting of side effect</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Valganciclovir Tablets 450mg contains:</strong></p><p>The active substance is Valganciclovir Hydrochloride.</p><p>Each film coated tablet contains 496.3mg of Valganciclovir Hydrochloride equivalent to 450mg of Valganciclovir.</p><p>The other ingredients are: cellulose microcrystalline, Crospovidone, Povidone, Stearic Acid, Purified Water</p><p>Film Coating: Opadry Pink 15B24005</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Valganciclovir Tablets 450mg looks like?

 

Pink, oval, biconvex, film-coated tablets, debossed with 'J' on one side and '156' on the



Other side.



How supplied:

 

Valganciclovir Tablets 450mg are supplied in blister pack.



Valganciclovir Tablets 450mg - container 3X10’s Alu-Alu blister



Not all pack sizes may be marketed.




            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p>&nbsp;</p><p>Saudi Amarox Industrial Company</p><p>&nbsp;</p><p>Aljameah Street, Malaz quarter, Riyadh 11441</p><p>Saudi Arabia</p><p>Tel: +966 11 477 221</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January, 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تنتمي فالقان 450 ملغم أقراص إلى مجموعة من الأدوية تسمى مضادات الفيروسات. وهي تعمل عن طريق إيقاف نمو الفيروسات. حيث تتحول المدة الفعالة داخل الجسم من فالقانسيكلوفير ، إلى قانسيكلوفير. ويعمل قانسيكلوفير على منع فيروس يسمى الفيروس المضخم للخلايا (CMV) من التكاثر وإصابة الخلايا السليمة. علما بأن المرضى الذين يعانون من ضعف الجهاز المناعي والمصابون بعدوى CMV في أعضاء الجسم. تكون هذه الإصابة مهددة للحياة.</p><p dir="RTL">تستخدم فالقان 450 ملغم أقراص من أجل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج عدوى CMV التي تصيب شبكية العين لدى المرضى البالغين والمصابين بمتلازمة نقص المناعة المكتسب (الإيدز). يمكن أن تسبب عدوى CMV&nbsp; في شبكية العين مشاكل في الرؤية تصل إلى العمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع الإصابة بعدوى فيروس المضخم للخلايا CMV بعد زرع الأعضاء (في البالغين الأطفال)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال فالقان 450 ملغم أقراص :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من فالقانسيكلوفير أو قانسيكلوفيرأو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في مرحلة الرضاعة الطبيعية.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول فالقان 450 ملغم أقراص إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أسيكلوفير أو بنسيكلوفير أو فالاسيكلوفير أو فامسيكلوفير. هذه أدوية تستخدم في الالتهابات الفيروسية.</p><p dir="RTL"><strong>تحذيرات خاصة باستعمال فالقان 450 ملغم أقراص </strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك انخفاض في عدد خلايا الدم البيضاء أو خلايا الدم الحمراء أو الصفائح الدموية (خلايا صغيرة تشارك في تخثر الدم) في الدم. سيقوم طبيبك بإجراء فحوصات الدم قبل البدء في تناول فالقان 450 ملغم أقراص وسيتم إجراء المزيد من الاختبارات أثناء تناولك للأقراص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج الإشعاعي أو غسيل الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في كليتيك. قد يحتاج طبيبك إلى وصف جرعة مخفضة لك وقد يحتاج إلى فحص دمك بشكل متكرر أثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليًا كبسولات قانسيكلوفير ويريد طبيبك منك التبديل إلى فالقان 450 ملغم أقراص. من المهم ألا تتناول أكثر من عدد الأقراص التي يصفها طبيبك حتى لا تتعرض لمخاطر الجرعة الزائدة.</p><p dir="RTL"><strong>تناول أدوية أخرى مع فالقان 450 ملغم أقراص </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية أخرى مؤخرًا. بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية ، والأدوية العشبية.</p><p dir="RTL">إذا كنت تتناول أدوية أخرى في نفس الوقت الذي تتناول فيه فالقان 450 ملغم أقراص ، فإن ذلك قد يؤثر على كمية الدواء التي تدخل في مجرى الدم أو قد تسبب تأثيرات ضارة. أخبر طبيبك إذا كنت تتناول بالفعل أدوية تحتوي على أي مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيميبينيم سيلاستاتين (مضاد حيوي) حيث أن تناول إيميبينيم سيلاستاتين مع فالقان 450 ملغم أقراص يمكن أن يسبب التشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفودين ، ديدانوسين ، لاميفودين ، ستافودين ، تينوفوفير ، أباكافير ، إمتريتيتابين أو أنواع مماثلة من الأدوية المستخدمة لعلاج الإيدز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أديفوفير أو أي أدوية أخرى تستخدم لعلاج التهاب الكبد B</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البروبينسيد (دواء لعلاج النقرس). حيث أن تناول البروبينسيد مع فالقان 450 ملغم أقراص في نفس الوقت يمكن أن يزيد من كمية القانسيكلوفير في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميكوفينولات موفيتيل ، سيكلوسبورين أو تاكروليموس (يستخدم بعد زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينكريستين ، فينبلاستين ، دوكسوروبيسين ، هيدروكسي يوريا أو أنواع مماثلة من الأدوية المستخدمة لعلاج السرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على تراي ميثوبريم ، تراي ميثوبريم / سلفا ودابسون (مضادات حيوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنتاميدين (دواء لعلاج الطفيليات أو التهابات الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكيتوزين أو الأمفوتريسين B (أدوية مضادة للفطريات)</p><p dir="RTL"><strong>تناول فالقان 450 ملغم أقراص مع الطعام والشراب</strong></p><p dir="RTL">ينبغي أن تتناول فالقان 450 ملغم أقراص مع الطعام. إذا كنت غير قادر على تناول الطعام لأي سبب من الأسباب ، يجب أن تستمر في تناول جرعة فالقان 450 ملغم أقراص كالمعتاد.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً فيجب عدم تتناول فالقان 450 ملغم أقراص إلا إذا أوصى طبيبك بذلك. إذا كنت حاملاً أو تخطط للحمل ، يجب عليك إخبار طبيبك. حيث أن تناول فالقان 450 ملغم أقراص أثناء الحمل قد يؤذي طفلك الذي لم يولد بعد.</p><p dir="RTL">إذا كنت مرضعة فيجب عدم تتناول فالقان 450 ملغم أقراص. إذا أراد طبيبك بدأ العلاج بتناول فالقان 450 ملغم أقراص ، فيجب عليك التوقف عن الرضاعة الطبيعية قبل البدء في تناول الأقراص.</p><p dir="RTL">يجب على النساء في سن الإنجاب استخدام وسائل منع الحمل الفعالة عند تناول أقراص فالقان 450 ملغم أقراص ولمدة 30 يومًا على الأقل بعد انتهاء العلاج.</p><p dir="RTL">يجب على الرجال الذين يمكن أن تصبح شركاؤهم حاملا استخدام الواقي الذكري أثناء تناول أقراص فالقان 450 ملغم أقراص ويجب أن يستمروا في استخدام الواقي الذكري لمدة 90 يومًا بعد انتهاء العلاج.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقود أو تستخدم الآلات إذا كنت تشعر بالدوار أو التعب أو الاهتزاز أو عدم الإتزان أثناء تناول هذا الدواء.</p><p dir="RTL">اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد .</p><p dir="RTL">يجب عليك الحذرا أثناء التعامل مع الأقراص. لا تكسرها أو تسحقها. يجب أن تبتلعهم بالكامل ومع الطعام كلما أمكن ذلك. إذا قمت بلمس الأقراص التالفة بطريق الخطأ ، اغسل يديك جيدًا بالماء والصابون. في حالة وصول أي مسحوق من الأقراص إلى عينيك ، اشطف عينيك بالماء المعقم أو بالماء النظيف إذا لم يكن لديك ماء معقم.</p><p dir="RTL"><strong>يجب أن تلتزم بتناول عدد الأقراص المحدد حسب تعليمات طبيبك لتجنب آثار الجرعة الزائدة.</strong></p><p dir="RTL">ينبغي أن تتناول فالقان 450 ملغم أقراص مع الطعام ، كلما كان ذلك ممكنا ، - انظر القسم 2.</p><p dir="RTL"><strong>البالغين:</strong></p><p dir="RTL"><strong>الوقاية من مرض </strong><strong>CMV</strong><strong> في حالة مرضى زرع الأعضاء</strong></p><p dir="RTL">يجب أن تبدأ في تناول هذا الدواء في غضون 10 أيام من عملية الزرع. الجرعة المعتادة هي قرصين يتم تناولهم مرة واحدة يوميًا. يجب أن تستمر في تناول هذه الجرعة لمدة تصل إلى 100 يوم بعد عملية الزرع. إذا كانت العملية هي زرع كلى ، فقد ينصحك طبيبك بتناول الأقراص لمدة 200 يوم.</p><p dir="RTL"><strong>علاج </strong><strong>عدوى </strong><strong>CMV</strong><strong> في شبكية العين</strong><strong> في مرضى الإيدز (يسمى العلاج الحثي)</strong></p><p dir="RTL">الجرعة المعتادة من فالقان 450 ملغم أقراص هي قرصان يتم تناولهم مرتين في اليوم لمدة 21 يومًا (ثلاثة أسابيع). لا تتناول هذه الجرعة لأكثر من 21 يومًا ما لم يخبرك طبيبك بذلك ، لأن ذلك قد يزيد من خطر حدوث آثار جانبية محتملة.</p><p dir="RTL"><strong>علاج طويل الأمد لمنع تكرار عدوى </strong><strong>CMV</strong><strong> في شبكية العين في مرضى الإيدز الذين لديهم عدوى </strong><strong>CMV</strong><strong> (يسمى علاج المداومة)</strong></p><p dir="RTL">الجرعة المعتادة من فالقان 450 ملغم أقراص هي قرصان يتم تناولهم مرة واحدة في اليوم يجب أن تحاول تناول الأقراص كل يوم في نفس الوقت. سينصحك طبيبك بالفترة التي يجب أن تستمر في تناول فالقان 450 ملغم أقراص خلالها. إذا تفاقمت عدوى الشبكية أثناء تناولك لهذه الجرعة ، فقد يخبرك طبيبك بتكرار العلاج الحثي (على النحو الوارد أعلاه) أو قد يقرر إعطائك دواء آخر لعلاج عدوى CMV.</p><p dir="RTL"><strong>المرضى المسنين</strong></p><p dir="RTL">لم تدرس تأثيرات تناول فالقان 450 ملغم أقراص على المرضى المسنين.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p dir="RTL">إذا كانت كليتيك لا تعملان بشكل صحيح ، فقد يوصيك طبيبك بتناول عدد أقل من الأقراص كل يوم أو أن تتناول أقراصك في أيام معينة كل أسبوع. من المهم جدًا أن تتناول فقط عدد الأقراص التي وصفها طبيبك.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكبد</strong></p><p dir="RTL">لم تدرس تأثيرات تناول فالقان 450 ملغم أقراص في المرضى الذين يعانون من مشاكل في الكبد.</p><p dir="RTL"><strong>استخدام فالقان 450 ملغم أقراص في الأطفال والمراهقين:</strong></p><p dir="RTL"><strong>الوقاية من مرض </strong><strong>CMV</strong><strong> في حالة مرضى زرع الأعضاء</strong></p><p dir="RTL">يجب أن يبدأ الأطفال بتناول هذا الدواء في غضون 10 أيام من عملية الزرع. وتختلف الجرعة المقدمة حسب حجم الطفل ويجب أن تؤخذ مرة واحدة يوميًا. سيقرر طبيبك الجرعة الأنسب بناءً على طول طفلك ووزنه ووظائف الكلي. يجب أن تستمر في هذه الجرعة لمدة تصل إلى 100 يوم. إذا كانت حالة الطفل هي عملية زرع كلى ، فقد ينصحك طبيبك بتناول الجرعة لمدة 200 يوم.</p><p dir="RTL">للأطفال الذين لا يستطيعون ابتلاع فالقان 450 ملغم أقراص المغطاة بطبقة رقيقة ، يمكن استخدام مسحوق فالقان 450 ملغم والمعد للحل ثم التناول عن طريق الفم.</p><p dir="RTL"><strong>الجرعة الزائدة من فالقان 450 ملغم أقراص</strong></p><p dir="RTL">اتصل بطبيبك أو المستشفى على الفور إذا كنت قد تناولت ، أو كنت تعتقد أنك تناولت ، أقراصًا أكثر مما يجب. تناول الكثير من الأقراص يمكن أن يسبب آثارًا جانبية خطيرة ، لا سيما التي تؤثر على الدم أو الكلى. قد تحتاج إلى علاج في المستشفى.</p><p dir="RTL"><strong>نسيان تناول أقراص من فالقان 450 ملغم أقراص</strong></p><p dir="RTL">إذا نسيت تناول جرعة فالقان 450 ملغم أقراص ، تناولها حينما تتذكرها ثم تناول الجرعة التالية في الوقت المعتاد. لا تتناول جرعة مضاعفة لتعويض أقراص منسية.</p><p dir="RTL"><strong>التوقفت عن تناول أقراص من فالقان 450 ملغم أقراص</strong></p><p dir="RTL">يجب عدم التوقف عن تناول الدواء إلا إذا أخبرك طبيبك بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">الأعراض التي تحتاج إلى ملاحظتها</p><p dir="RTL">تفاعلات الحساسية</p><p dir="RTL">قد يصاب شخص واحد من بين كل 1000 شخص برد فعل مفاجئ وحاد تجاه مادة فالقانسيكلوفير (صدمة الحساسية). يجب التوقف عن تناول فالقان 450 ملغم أقراص وانتقل إلى قسم الحوادث والطوارئ في أقرب مستشفى إذا واجهت أيًا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مرتفع وحكة (الارتكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مفاجئ في الحلق والوجه والشفتين والفم مما قد يسبب صعوبة في البلع أو التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مفاجئ في اليدين أو القدمين أو الكاحلين.</p><p dir="RTL"><strong>آثار جانبية خطيرة</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أي من الآثار الجانبية الخطيرة التالية - وقد يخبرك طبيبك بالتوقف عن تناول فالقان 450 ملغم أقراص وقد تحتاج إلى علاج طبي عاجل:</p><p dir="RTL"><strong>شائع جدًا:</strong> قد يؤثر على أكثر من شخص من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء - مع وجود أعراض العدوى مثل التهاب الحلق ، وقرحة الفم أو الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء - وتشمل الأعراض على الشعور بضيق في التنفس أو التعب ، أو خفقان أو بشرة شاحبة</p><p dir="RTL"><strong>شائع:</strong> قد يؤثر على شخص واحد من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الدم (تسمم الدم) - تشمل الأعراض على الحمى والقشعريرة والخفقان والارتباك وغموض بالكلام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصفائح الدموية - وتشمل الأعراض على النزيف أو ظهور الكدمات بسهولة أكثر من المعتاد ، ظهور الدم في البول أو البراز أو النزيف من اللثة ، قد يكون هذا النزيف حاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حاد في عدد خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس - علامات ألم شديد في المعدة ينتشر في ظهرك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات</p><p dir="RTL"><strong>غير شائع:</strong> قد يؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل نخاع العظم في إنتاج خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة - سماع أو رؤية أشياء غير حقيقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار أو مشاعر غير طبيعية ، وفقدان الواقعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فشل وظائف الكلى</p><p dir="RTL">الآثار الجانبية التالية حدثت أثناء العلاج بتناول فالغانسيكلوفير أو غانسيكلوفير:</p><p dir="RTL">الآثار الجانبية الأخرى</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرض إذا لاحظت أيًا من الآثار الجانبية التالية:</p><p dir="RTL">آثار جانبية شائع جدًا: قد تؤثر على أكثر من شخص من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلاع والقلاع الفموي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي (مثل التهاب الجيوب الأنفية والتهاب اللوزتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع بطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأكزيما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى.</p><p dir="RTL">آثار جانبية شائعة: قد تؤثر على شخص واحد من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى البول - أعراض الحمى ، معدل تمرير البول أكثر من الطبيعي ، والشعور بالألم عند تمرير البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الجلد والأنسجة تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي خفيف - قد تشمل أعراضه على أحمرار بالجلد والحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالاكتئاب أو القلق أو الخلط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف أو الخدر في اليدين أو القدمين مما قد يؤثر على توازنك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في درجة إحساسك باللمس ، أو الوخز ، أو الدغدغة ، أو الوخز ، أو الشعور بالحرقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في درجة &nbsp;إحساسك بتذوق الأشياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين (التهاب الملتحمة) ، ألم في العين أو مشاكل في البصر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم ، مما قد يجعلك تشعر بالدوار أو الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك ، والرياح ، وعسر الهضم ، وآلام في المعدة ، وتورم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات وظائف الكبد والكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق ليلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة والطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر ، آلام العضلات أو المفاصل ، تشنجات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو الضعف أو الإعياء بشكل عام</p><p dir="RTL">آثار جانبية غير شائعة: قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإثارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهزة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصمم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أرتكاريا ، جفاف بالجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقم عند الرجال - انظر قسم &quot;الخصوبة&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">لم يحدث فصل بطانة العين الداخلية (شبكية العين المنفصلة) إلا في مرضى الإيدز الذين عولجوا بتناول فالقان 450 ملغم أقراص لعدوى CMV.</p><p dir="RTL">آثار جانبية إضافية في الأطفال والمراهقين:</p><p dir="RTL">تتشابه الآثار الجانبية المبلغ عنها عند الأطفال والمراهقين مع الآثار الجانبية المبلغ عنها عند البالغين.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه) . بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم فالقان 450 ملغم أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا الدواء لا يتطلب أي شروط تخزين خاصة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة . هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه فالقان 450 ملغم أقراص 450 ملغم</strong></p><p dir="RTL">المادة الفعالة هي فالغانسيكلوفير هيدروكلوريد.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 496.3 ملغم فالغانسيكلوفير هيدروكلوريد مايكافئ فالغانسيكلوفير 450 ملغم .</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: السليلوز دقيق التبلور ، كروسبوفيدون ، بوفيدون ، حمض&nbsp;الستياريك ، المياه النقية.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: هيبروميلوز 2910 ، ثاني أكسيد التيتانيوم ، بولي إيثيلين جليكول / ماكروجول ،أكسيد الحديد الأحمر ، بولي سوربات 80 .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل فالقان 450 ملغم أقراص ومحتويات العلبة ؟</strong></p><p dir="RTL"><strong>فالقان 450 ملغم أقراص 450 ملغم</strong></p><p dir="RTL">أقراص وردية بيضاوية الشكل محدبة الوجهين، والأقراص مغلفة بطبقة رقيقة و مدموغة بحرف &quot;J&quot; من جانب و &quot;156&quot; على الجانب الآخر.</p><p dir="RTL"><strong>توافر فالقان 450 ملغم أقراص :</strong></p><p dir="RTL">يتوافر فالقان 450 ملغم أقراص في عبوات حاوية .</p><p dir="RTL">تحتوي عبوة فالقان 450 ملغم أقراص 450 ملغم على 30 قرص عبارة عن ثلاثة شرائط بكل منها 10 أقراص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية .</p><p dir="RTL">تليفون: &nbsp;+ 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             نوفمبر/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valganciclovir Tablets 450mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 496.3mg of Valganciclovir Hydrochloride equivalent to 450mg of Valganciclovir. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valganciclovir Tablets 450mg 
Pink, oval, biconvex, film-coated tablets, debossed with 'J' on one side and '156' on the Other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valganciclovir is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).&nbsp;</p><p>Valganciclovir is indicated for the prevention of CMV disease in CMV-negative adults and children&nbsp; (aged from birth to 18 years) who have received a solid organ transplant from a CMVpositive donor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology&nbsp;</p><p><strong>Caution &ndash; Strict adherence to dosage recommendations is essential to avoid overdose (see sections 4.4 and 4.9).&nbsp; </strong></p><p>Valganciclovir is rapidly and extensively metabolized to ganciclovir after oral dosing. Oral</p><p>Valganciclovir 900mg b.i.d. is therapeutically equivalent to intravenous ganciclovir 5mg/kg b.i.d.&nbsp;</p><p>&nbsp;</p><p>Treatment of cytomegalovirus (CMV) retinitis&nbsp;</p><p><u>Adult patients</u>&nbsp;&nbsp;</p><p>Induction treatment of CMV retinitis&nbsp;</p><p>For patients with active CMV retinitis, the recommended dose is 900 mg valganciclovir (two</p><p>Valganciclovir 450 mg tablets) twice a day for 21 days and, whenever possible, taken with food.</p><p>Prolonged induction treatment may increase the risk of bone marrow toxicity (see section 4.4).</p><p><u>Maintenance treatment of CMV retinitis:</u>&nbsp;</p><p>Following induction treatment, or in patients with inactive CMV retinitis, the recommended dose is 900mg valganciclovir (two Valganciclovir 450 mg tablets) once daily and, whenever possible, taken with food. Patients whose retinitis worsens may repeat induction treatment; however, consideration should be given to the possibility of viral drug resistance.</p><p>The duration of maintenance treatment should be determined on an individual basis.</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of Valganciclovir in the treatment of CMV retinitis have not been established in adequate and well-controlled clinical studies in paediatric patients.</p><p>Prevention of CMV disease in solid organ transplantation&nbsp;</p><p>Adult patients&nbsp;</p><p>For kidney transplant patients, the recommended dose is 900 mg (two Valganciclovir 450 mg tablets) once daily, starting within 10 days post-transplantation and continuing until 100 days post-transplantation. Prophylaxis may be continued until 200 days post-transplantation (see sections 4.4, 4.8 and 5.1).</p><p>For patients who have received a solid organ transplant other than kidney, the recommended dose is 900 mg (two Valganciclovir 450 mg tablets) once daily, starting within 10 days posttransplantation and continuing until 100 days post-transplantation.&nbsp;</p><p>Whenever possible, the tablets should be taken with food.</p><p>Pediatric population&nbsp;</p><p>In paediatric solid organ transplant patients, aged from birth, who are at risk of developing CMV disease, the recommended once daily dose of Valganciclovir is based on body surface area (BSA) and creatinine clearance (Clcr) derived from Schwartz formula (ClcrS), and is calculated using the equation below:</p><p>Paediatric Dose (mg) = 7 x BSA x ClcrS (see Mosteller BSA formula and Schwartz Creatinine Clearance formula below).&nbsp;</p><p>If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m2, then a maximum value of 150 mL/min/1.73m2 should be used in the equation:</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_42147" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:468pt;height:75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="624" height="100" alt="" vspace="0" hspace="0" border="0" style="width:624px;height:100px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_33305" o:spid="_x0000_s1029" style='width:406.4pt;height:32.75pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="51610,4160" o:gfxdata="UEsDBBQABgAIAAAAIQB8mo/THQEAAIMCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKRSTU/DMAy9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==
">
 <v:shape id="Picture_x0020_137" o:spid="_x0000_s1030" type="#_x0000_t75"
  style='position:absolute;width:51610;height:4160;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_139" o:spid="_x0000_s1031" type="#_x0000_t75"
  style='position:absolute;left:50619;top:3771;width:198;height:92;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg"
   o:title=""/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="542" height="44" alt="" vspace="0" hspace="0" border="0" style="width:542px;height:44px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:406.4pt;height:32.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>where k = 0.45* for patients aged &lt; 2 years, 0.55 for boys aged 2 to &lt; 13 years and girls aged 2 to 16 years, and 0.7 for boys aged 13 to 16 years. Refer to adult dosing for patients older than 16 years of age. The k values provided are based on the Jaffe method of measuring serum creatinine and may require correction when enzymatic methods are used.</p><p>*For appropriate sub-populations a lowering of k value may also be necessary (e.g. in paediatric patients with low birth weight).</p><p>For paediatric kidney transplant patients, the recommended once daily mg dose (7 x BSA x ClcrS) should start within 10 days post-transplantation and continue until 200 days posttransplantation. For paediatric patients who have received a solid organ transplant other than kidney, the recommended once daily mg dose (7x BSA x ClcrS) should start within 10 days post-transplantation and continue until 100 days post-transplantation.</p><p>All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered. The oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, Valganciclovir filmcoated tablets may be used if the calculated doses are within 10% of available tablet doses, and the patient is able to swallow tablets. For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken.</p><p>It is recommended to monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during the prophylaxis period.</p><p>Special dosage instructions</p><p>Pediatric population: Dosing of pediatric SOT patients is individualized based on a patient&#39;s renal function, together with body surface area.</p><p>Elderly patients:</p><p>Safety and efficacy have not been established in this patient population. No studies have been conducted in adults older than 65 years of age. Since renal clearance decreases with age, Valganciclovir should be administered to elderly patients with special consideration of their renal status (see table below) (See section 5.2).</p><p>Patients with renal impairment:</p><p>Serum creatinine levels or estimated creatinine clearance should be monitored carefully. Dosage adjustment is required according to creatinine clearance, as shown in the table below (see sections 4.4 and 5.2).</p><p>An estimated creatinine clearance (ml/min) can be related to serum creatinine by the following formulae:</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_36569" o:spid="_x0000_s1026" style='width:287.8pt;height:29.15pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="36553,3703" o:gfxdata="UEsDBBQABgAIAAAAIQB8mo/THQEAAIMCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKRSTU/DMAy9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">
 <v:shape id="Picture_x0020_201" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;width:36553;height:3703;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_203" o:spid="_x0000_s1028" type="#_x0000_t75"
  style='position:absolute;left:34770;top:3314;width:693;height:92;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
   o:title=""/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="384" height="39" alt="" vspace="0" hspace="0" border="0" style="width:384px;height:39px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:287.8pt;height:29.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>For females = 0.85 &times; male value</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Clcr (ml/min)</p></td><td style="vertical-align:top"><p>Induction dose of valganciclovir</p></td><td style="vertical-align:top"><p>Maintenance/Prevention &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dose</p><p>valganciclovir</p></td><td style="vertical-align:top"><p>of</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 60</p></td><td style="vertical-align:top"><p>900 mg (2 tablets) twice daily</p></td><td style="vertical-align:top"><p>900 mg (2 tablets) once daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>40 &ndash; 59</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) twice daily</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) once daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25 &ndash; 39</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) once daily</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) every 2 days</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 &ndash; 24</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) every 2 days</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) twice weekly</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p></td><td style="vertical-align:top"><p>Not recommended</p></td><td style="vertical-align:top"><p>Not recommended</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><u>Patients undergoing hemodialysis:</u>&nbsp;</p><p>For patients on haemodialysis (Clcr &lt; 10 ml/min) a dose recommendation cannot be given. Thus Valganciclovir film-coated tablets should not be used in these patients (see sections 4.4 and 5.2).</p><p><strong>Patients with hepatic impairment:&nbsp; </strong></p><p>Safety and efficacy of Valganciclovir tablets have not been established in patients with hepatic&nbsp;</p><p>impairment (see section 5.2).</p><p>Patients with severe leukopenia, neutropenia, anaemia, thrombocytopenia and pancytopenia:&nbsp;</p><p>See section 4.4 before initiation of therapy.&nbsp;</p><p>If there is a significant deterioration of blood cell counts during therapy with Valganciclovir, treatment&nbsp; with haematopoietic growth factors and/or dose interruption should be considered (see section 4.4).</p><p>Method of administration&nbsp;</p><p>Valganciclovir is administered orally, and whenever possible, should be taken with food (see section 5.2).</p><p>For pediatric patients who are unable to swallow Valganciclovir film-coated tablets, Valganciclovir powder for oral solution can be administered.</p><p>Precautions to be taken before handling or administering the medicinal product&nbsp;&nbsp;</p><p>The tablets should not be broken or crushed. Since Valganciclovir is considered a potential teratogen and carcinogen in humans, caution should be observed in handling broken tablets (see section 4.4). Avoid direct contact of broken or crushed tablets with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valganciclovir is contra-indicated in patients with hypersensitivity to Valganciclovir, ganciclovir or to any of the excipients listed in section 6.1. 
Valganciclovir is contra-indicated during breast-feeding (see section 4.6). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cross-hypersensitivity&nbsp;</u></p><p>Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should therefore be used when prescribing Valganciclovir to patients with known hypersensitivity to aciclovir or penciclovir, (or to their prodrugs, valaciclovir or famciclovir respectively).&nbsp;</p><p><u>Mutagenicity, teratogenicity, carcinogenicity, fertility, and contraception&nbsp;</u></p><p>Prior to the initiation of valganciclovir treatment, patients should be advised of the potential risks to the foetus. In animal studies, ganciclovir was found to be mutagenic, teratogenic, carcinogenic, and a suppressor of fertility. Valganciclovir should, therefore, be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers (see section 5.3). Based on clinical and nonclinical studies it is also considered likely that Valganciclovir causes temporary or permanent inhibition of spermatogenesis. Women of child bearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Men must be advised to practise barrier contraception during treatment, and for at least 90 days thereafter, unless it is certain that the female partner is not at risk of pregnancy (see sections 4.6, 4.8 and 5.3).</p><p>Valganciclovir has the potential to cause carcinogenicity and reproductive toxicity in the long term.</p><p><u>Myelosuppression&nbsp;</u></p><p>Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anemia have been observed in patients treated with Valganciclovir (and ganciclovir). Therapy should not be initiated if the absolute neutrophil count is less than 500 cells/&mu;l, or the platelet count is less than 25000/&mu;l, or the hemoglobin level is less than 8 g/dl (see sections 4.2 and 4.8).</p><p>When extending prophylaxis beyond 100 days the possible risk of developing leukopenia and neutropenia should be taken into account (see sections 4.2, 4.8 and 5.1).</p><p>Valganciclovir should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related hematological cytopenia and in patients receiving radiotherapy.&nbsp;</p><p>It is recommended that complete blood counts and platelet counts should be monitored regularly during therapy. Increased haematological monitoring may be warranted in patients with renal impairment and paediatrics, at a minimum each time the patient attends the transplant clinic. In patients developing severe leukopenia, neutropenia, anaemia and/or thrombocytopenia, it is recommended that treatment with haematopoietic growth factors and/or dose interruption be considered (see section 4.2).</p><p><u>Difference in bioavailability with oral ganciclovir&nbsp;&nbsp;</u></p><p>The bioavailability of ganciclovir after a single dose of 900 mg valganciclovir is approximately 60 %, compared with approximately 6 % after administration of 1000 mg oral ganciclovir (as capsules). Excessive exposure to ganciclovir may be associated with life-threatening adverse reactions. Therefore, careful adherence to the dose recommendations is advised when instituting therapy, when switching from induction to maintenance therapy and in patients who may switch from oral ganciclovir to valganciclovir as Valganciclovir cannot be substituted for ganciclovir capsules on a one-to-one basis. Patients switching from ganciclovir capsules should be advised of the risk of overdosage if they take more than the prescribed number of Valganciclovir tablets (see sections 4.2 and 4.9).&nbsp;</p><p><u>Renal impairment&nbsp;</u></p><p>In patients with impaired renal function, dosage adjustments based on creatinine clearance are required (see sections 4.2 and 5.2).</p><p>Valganciclovir film-coated tablets should not be used in patients on haemodialysis (see sections</p><p>4.2 and 5.2).</p><p><u>Use with other medicines&nbsp;</u></p><p>Seizures have been reported in patients taking imipenem-cilastatin and ganciclovir. Valganciclovir should not be used concomitantly with imipenem-cilastatin unless the potential benefits outweigh the potential risks (see section 4.5).</p><p>Patients treated with Valganciclovir and (a) didanosine, (b) drugs that are known to be myelosuppressive (e.g. zidovudine), or (c) substances affecting renal function, should be closely monitored for signs of added toxicity (see section 4.5).</p><p>The controlled clinical study using valganciclovir for the prophylactic treatment of CMV disease in transplantation, as detailed in section 5.1, did not include lung and intestinal transplant patients. Therefore, experience in these transplant patients is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In-vivo drug interaction studies with Valganciclovir have not been performed. Since valganciclovir is extensively and rapidly metabolised to ganciclovir; drug interactions associated with ganciclovir will be expected for valganciclovir.</p><p>Drug interactions with ganciclovir&nbsp;</p><p><u>Pharmacokinetic interactions</u>&nbsp;&nbsp;</p><p>Probenecid&nbsp;&nbsp;</p><p>Probenecid given with oral ganciclovir resulted in statistically significantly decreased renal clearance of ganciclovir (20 %) leading to statistically significantly increased exposure (40 %). These changes were consistent with a mechanism of interaction involving competition for renal tubular secretion. Therefore, patients taking probenecid and valganciclovir should be closely monitored for ganciclovir toxicity.</p><p>Didanosine&nbsp;</p><p>Didanosine plasma concentrations were found to be consistently raised when given with IV ganciclovir. At intravenous doses of 5 and 10 mg/kg/day, an increase in the AUC of didanosine ranging from 38 to 67% has been observed confirming a pharmacokinetic interaction during the concomitant administration of these drugs. There was no significant effect on ganciclovir concentrations. Patients should be closely monitored for didanosine toxicity e.g pancreatitis (see section 4.4).<strong> </strong></p><p>Other antiretrovirals&nbsp;</p><p>Cytochrome P450 isoenzymes play no role in ganciclovir pharmacokinetics. As a consequence, pharmacokinetic interactions with protease inhibitors and non-nucleoside reverse transcriptase inhibitors are not anticipated.</p><p><strong>Pharmacodynamic interactions&nbsp;&nbsp; </strong></p><p>Imipenem-cilastatin&nbsp;</p><p>Seizures have been reported in patients taking ganciclovir and imipenem-cilastatin concomitantly and a pharmacodynamic interaction between these two drugs cannot be discounted. These drugs should not be used concomitantly unless the potential benefits outweigh the potential risks (see section 4.4).</p><p>Zidovudine&nbsp;</p><p>Both zidovudine and ganciclovir have the potential to cause neutropenia and anaemia. A pharmacodynamic interaction may occur during concomitant administration of these drugs.</p><p>Some patients may not tolerate concomitant therapy at full dosage (see section 4.4).</p><p>Potential drug interactions&nbsp;</p><p>Toxicity may be enhanced when ganciclovir/valganciclovir is co-administered with other drugs known to be myelosuppressive or associated with renal impairment. This includes nucleoside (e.g. zidovudine, didanosine, stavudine) and nucleotide analogues (e.g. tenofovir, adefovir), immunosuppressants (e.g. ciclosporin, tacrolimus, mycophenolate mofetil), antineoplastic agents (e.g. doxorubicin, vinblastine, vincristine, hydroxyurea) and anti-infective agents (trimethoprim/sulphonamides, dapsone, amphotericin B, flucytosine, pentamidine). Therefore,<strong> </strong>these drugs should only be considered for concomitant use with valganciclovir if the potential benefits outweigh the potential risks (see section 4.4). actions with other medicinal products and other forms of interactions<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Contraception in males and females&nbsp;</strong></p><p>As a result of the potential for reproductive toxicity and teratogenicity, women of childbearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Male patients must be advised to practice barrier contraception during and for at least 90 days following treatment with valganciclovir unless it is certain that the female partner is not at risk of pregnancy (see sections 4.4 and 5.3).&nbsp;</p><p><strong>Pregnancy&nbsp;</strong></p><p>The safety of Valganciclovir for use in pregnant women has not been established. Its active metabolite, ganciclovir, readily diffuses across the human placenta. Based on its pharmacological mechanism of action and reproductive toxicity observed in animal studies with ganciclovir (see section 5.3) there is a theoretical risk of teratogenicity in humans.</p><p>Valganciclovir should not be used in pregnancy unless the therapeutic benefit for the mother outweighs the potential risk of teratogenic damage to the foetus.</p><p><strong>Breast-feeding&nbsp;</strong></p><p>It is unknown if ganciclovir is excreted in human breast milk, but the possibility of ganciclovir being excreted in the breast milk and causing serious adverse reactions in the nursing infant cannot be discounted. Animal data indicate that ganciclovir is excreted in the milk of lactating rats. Therefore, breast-feeding must be discontinued during treatment with valganciclovir (see sections 4.3 and 5.3).</p><p><strong>Fertility&nbsp;</strong></p><p>A small clinical study with renal transplant patients receiving Valganciclovir for CMV prophylaxis for up to 200 days demonstrated an impact of valganciclovir on spermatogenesis, with decreased sperm density and motility measured after treatment completion. This effect appears to be reversible and approximately six months after Valganciclovir discontinuation, mean sperm density and motility recovered to levels comparable to those observed in the untreated controls.</p><p>In animal studies, ganciclovir impaired fertility in male and female mice and has shown to inhibit spermatogenesis and induce testicular atrophy in mice, rats and dogs at doses considered clinically relevant.</p><p>Based on clinical and nonclinical studies, it is considered likely that ganciclovir (and valganciclovir) may cause temporary or permanent inhibition of human spermatogenesis (see sections 4.4 and 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on ability to drive and use machines have been performed.</p><p>Adverse reactions such as seizures, dizziness, and confusion have been reported with the use of Valganciclovir and/or ganciclovir. If they occur, such effects may affect tasks requiring alertness, including the patient&#39;s ability to drive and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;a Summary of the safety profile&nbsp;&nbsp; </strong></p><p>Valganciclovir is a prodrug of ganciclovir, which is rapidly and extensively metabolised to ganciclovir after oral administration. The undesirable effects known to be associated with ganciclovir use can be expected to occur with valganciclovir. All of the adverse drug reactions observed in valganciclovir clinical studies have been previously observed with ganciclovir. Therefore, adverse drug reactions reported with IV or oral ganciclovir (formulation no longer available) or with valganciclovir are included in the table of adverse drug reactions below.</p><p>In patients treated with valganciclovir/ganciclovir the most serious and frequent adverse drug reactions are haematological reactions and include neutropenia, anaemia and thrombocytopenia &ndash; see section 4.4.</p><p>The frequencies presented in the table of adverse reactions are derived from a pooled population of patients (n=1704) receiving maintenance therapy with ganciclovir or valganciclovir. Exception is made for anaphylactic reaction, agranulocytosis and granulocytopenia, the frequencies of which are derived from post-marketing experience. Adverse reactions are listed according to MedDRA system organ class. Frequency categories are defined using the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000).</p><p>The overall safety profile of ganciclovir/valganciclovir is consistent in HIV and transplant populations except that retinal detachment has only been reported in patients with CMV retinitis. However, there are some differences in the frequency of certain reactions. Valganciclovir is associated with a higher risk of diarrhoea compared to intravenous ganciclovir. Pyrexia, candida infections, depression, severe neutropenia (ANC &lt;500/&mu;L) and skin reactions are reported more frequently in patients with HIV. Renal and hepatic dysfunction are reported more frequently in organ transplant recipients.</p><p><strong><em>b Tabulated list of adverse drug reactions</em> </strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p><strong>ADR</strong>&nbsp;</p><p><strong>(MedDRA) </strong>&nbsp;</p><p><strong>System Organ Class</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Frequency Category</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Candida infections including oral candidiasis.</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Influenza</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Cellulitis</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow failure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td rowspan="3" style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Agranulocytosis*</p></td></tr><tr><td style="vertical-align:top"><p>Granulocytopenia*</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Immune system disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction*</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolic and nutrition disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Confusional state</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td rowspan="4" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Psychotic disorder</p></td></tr><tr><td style="vertical-align:top"><p>Thinking abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Hallucinations</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous system disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td rowspan="7" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Seizure</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia (taste disturbance)</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Eye disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment</p></td><td rowspan="6" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal detachment**</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous floaters</p></td></tr><tr><td style="vertical-align:top"><p>Eye pain</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p>Macular oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear and labyrinth disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Deafness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em> </strong><em>:</em>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmias</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular disorders</em> </strong><em>:</em>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders:</em> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p>Cough</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastrointestinal disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td rowspan="4" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td rowspan="8" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain upper</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Mouth ulceration</p></td></tr><tr><td style="vertical-align:top"><p>Dysphagia</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distention</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Hepato-biliary disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissues disorders:</em> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Night sweats</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculo-skeletal and connective tissue disorders:</em> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Renal and urinary disorders:</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal impairment</p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance renal decreased&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Reproductive system and breast disorders:</em> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infertility male</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General disorders and administration site conditions:</em> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p><em>*The frequencies of these adverse reactions are derived from post-marketing experience</em></p><p><em>**Retinal detachment has only been reported in HIV patients treated for CMV retinitis</em>&nbsp;</p><p>Description of selected adverse reactions&nbsp;</p><p><em>Neutropenia</em>&nbsp;</p><p>The risk of neutropenia is not predictable on the basis of the number of neutrophils before treatment. Neutropenia usually occurs during the first or second week of induction therapy. The cell count usually normalizes within 2 to 5 days after discontinuation of the drug or dose reduction (see section 4.4).</p><p><em>&nbsp;Thrombocytopenia</em>&nbsp;</p><p>Patients with low baseline platelet counts (&lt; 100,000 /&mu;L) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with AIDS (see section 4.4). Severe thrombocytopenia may be associated with potentially life-threatening bleeding.</p><p><em>Influence of treatment duration or indication on adverse reactions</em>&nbsp;</p><p>Severe neutropenia (ANC &lt;500/&mu;L) is seen more frequently in CMV retinitis patients (14%) undergoing treatment with Valganciclovir, intravenous or oral ganciclovir than in solid organ transplant patients receiving Valganciclovir or oral ganciclovir. In patients receiving valganciclovir or oral ganciclovir until Day 100 post-transplant, the incidence of severe neutropenia was 5% and 3% respectively, whilst in patients receiving Valganciclovir until Day 200 post-transplant the incidence of severe neutropenia was 10%.&nbsp;</p><p>There was a greater increase in serum creatinine seen in solid organ transplant patients treated until Day 100 or Day 200 post-transplant with both valganciclovir and oral ganciclovir when compared to CMV retinitis patients. However, impaired renal function is a feature common in solid organ transplantation patients.</p><p>The overall safety profile of Valganciclovir did not change with the extension of prophylaxis up to 200 days in high risk kidney transplant patients. Leukopenia was reported with a slightly higher incidence in the 200 days arm while the incidence of neutropenia, anaemia and thrombocytopenia were similar in both arms. <strong><em>c Paediatric population</em> </strong>&nbsp;</p><p>Valganciclovir has been studied in 179 paediatric solid organ transplant patients who were at risk of developing CMV disease (aged 3 weeks to 16 years) and in 133 neonates with symptomatic congenital CMV disease (aged 2 to 31 days), with duration of ganciclovir exposure ranging from 2 to 200 days.&nbsp;</p><p>The most frequently reported adverse reactions on treatment in paediatric clinical trials were diarrhoea, nausea, neutropenia, leukopenia and anaemia.&nbsp;</p><p>In solid organ transplant patients, the overall safety profile was similar in paediatric patients as compared to adults. Neutropenia was reported with slightly higher incidence in the two studies conducted in paediatric solid organ transplant patients as compared to adults, but there was no correlation between neutropenia and infectious adverse events in the paediatric population. A higher risk of cytopenias in neonates and infants warrants careful monitoring of blood counts in these age groups (see section 4.4).&nbsp;</p><p>In kidney transplant paediatric patients, prolongation of valganciclovir exposure up to 200 days was not associated with an overall increase in the incidence of adverse events. The incidence of severe neutropenia (ANC &lt; 500/&micro;L) was higher in paediatric kidney patients treated until Day 200 as compared to paediatric patients treated until Day 100 and as compared to adult kidney transplant patients treated until Day 100 or Day 200 (see section 4.4).</p><p>Only limited data are available in neonates or infants with symptomatic congenital CMV infection treated with Valganciclovir, however the safety appears to be consistent with the known safety profile of valganciclovir/ganciclovir.</p><p>Reporting of suspected adverse reactions&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>o Other GCC States: </strong><br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose experience with valganciclovir and intravenous ganciclovir&nbsp;</p><p>It is expected that an overdose of valganciclovir could possibly result in increased renal toxicity (see sections 4.2 and 4.4).</p><p>Reports of overdoses with intravenous ganciclovir, some with fatal outcomes, have been received from clinical trials and during post-marketing experience. In some of these cases no adverse events were reported. The majority of patients experienced one or more of the following adverse events:</p><p>-&nbsp;&nbsp; Haematological toxicity: myelosuppression including pancytopenia, bone marrow failure,&nbsp;&nbsp;&nbsp;&nbsp; leukopenia, neutropenia, granulocytopenia.</p><p>-&nbsp;&nbsp; Hepatotoxicity: hepatitis, liver function disorder.</p><p>-&nbsp;&nbsp; Renal toxicity: worsening of haematuria in a patient with pre-existing renal impairment, acute&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney injury, elevated creatinine.</p><p>-&nbsp;&nbsp; Gastrointestinal toxicity: abdominal pain, diarrhoea, vomiting.</p><p>-&nbsp;&nbsp; Neurotoxicity: generalised tremor, seizure.</p><p>Haemodialysis and hydration may be of benefit in reducing blood plasma levels in patients who receive an overdose of Valganciclovir (see section 5.2)</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: 5&alpha;-reductase inhibitor. ATC code : J05A B14</p><p>Mechanism of action&nbsp;</p><p>Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. After oral administration, valganciclovir is rapidly and extensively metabolised to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2&#39;-deoxyguanosine and inhibits replication of herpes viruses <em>in vitro</em> and <em>in vivo</em>. Sensitive human viruses include human cytomegalovirus</p><p>(HCMV), herpes simplex virus-1 and -2 (HSV-1 and HSV-2), human herpes virus -6, -7 and -8 (HHV-6, HHV-7, HHV8), Epstein-Barr virus (EBV), varicella-zoster virus (VZV) and hepatitis B virus (HBV).&nbsp;</p><p>In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97. Further phosphorylation occurs by cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolised intracellularly. Triphosphate metabolism has been shown to occur in HSV- and HCMV- infected cells with half-lives of 18 and between 6 and 24 hours respectively, after the removal of extracellular ganciclovir. As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells.The virustatic activity of ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosinetriphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation.</p><p>Antiviral activity&nbsp;</p><p>The in-vitro anti-viral activity, measured as IC<sub>50</sub> of ganciclovir against CMV, is in the range of</p><p>0.08 &mu;M (0.02 &mu;g/ml) to 14 &mu;M (3.5 &mu;g/ml). The clinical antiviral effect of Valganciclovir has been demonstrated in the treatment of AIDS patients with newly diagnosed CMV retinitis. CMV shedding was decreased in urine from 46 % (32/69) of patients at study entry to 7 % (4/55) of patients following four weeks of Valganciclovir treatment.</p><p><u>Clinical efficacy and safety</u>&nbsp;</p><p>Adult patients&nbsp;</p><p><em>Treatment of CMV retinitis:</em>&nbsp;</p><p>Patients with newly diagnosed CMV retinitis were randomised in one study to induction therapy with either Valganciclovir 900 mg b.i.d or intravenous ganciclovir 5 mg/kg b.i.d. The proportion of patients with photographic progression of CMV retinitis at week 4 was comparable in both treatment groups, 7/70 and 7/71 patients progressing in the intravenous ganciclovir and valganciclovir arms respectively.</p><p>Following induction treatment dosing, all patients in this study received maintenance treatment with Valganciclovir given at the dose of 900 mg once daily. The mean (median) time from randomisation to progression of CMV retinitis in the group receiving induction and maintenance treatment with Valganciclovir was 226 (160) days and in the group receiving induction treatment with intravenous ganciclovir and maintenance treatment with Valganciclovir was 219 (125) days.</p><p><em>Prevention of CMV disease in transplantation:</em>&nbsp;</p><p>A double-blind, double-dummy, clinical active comparator study has been conducted in heart, liver and kidney transplant patients (lung and gastro-intestinal transplant patients were not included in the study) at high-risk of CMV disease (D+/R-) who received either Valganciclovir (900 mg od) or oral ganciclovir (1000 mg t.i.d.) starting within 10 days of transplantation until Day 100 post-transplant. The incidence of CMV disease (CMV syndrome + tissue invasive disease) during the first 6 months post-transplant was 12.1 % in the Valganciclovir arm (n=239) compared with 15.2 % in the oral ganciclovir arm (n=125). The large majority of cases occurred following cessation of prophylaxis (post-Day 100) with cases in the valganciclovir arm occurring on average later than those in the oral ganciclovir arm. The incidence of acute rejection in the first 6 months was 29.7 % in patients randomised to valganciclovir compared with 36.0 % in the oral ganciclovir arm, with the incidence of graft loss being equivalent, occurring in 0.8 % of patients, in each arm.&nbsp;</p><p>A double-blind, placebo controlled study has been conducted in 326 kidney transplant patients at high risk of CMV disease (D+/R-) to assess the efficacy and safety of extending Valganciclovir CMV prophylaxis from 100 to 200 days post-transplant. Patients were randomized (1:1) to receive Valganciclovir tablets (900 mg od) within 10 days of transplantation either until Day 200 post-transplant or until Day 100 post-transplant followed by 100 days of placebo.</p><p>The proportion of patients who developed CMV disease during the first 12 months posttransplant is shown in the table below.</p><p>Percentage of Kidney Transplant Patients with CMV Disease<sup>1</sup>, 12 Month ITT Population <sup>A</sup>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Valganciclovir </strong>&nbsp;</p><p><strong>900 mg od</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Valganciclovir </strong>&nbsp;</p><p><strong>900 mg od</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Between Treatment Group Difference</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>100 Days </strong>&nbsp;</p><p><strong>(N = 163)</strong></p></td><td style="vertical-align:top"><p><strong>200 Days</strong>&nbsp;</p><p><strong>(N = 155)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Patients with confirmed or assumed</p><p>CMV disease<sup>2</sup></p></td><td style="vertical-align:top"><p>71 (43.6%)</p><p>[35.8% ; 51.5%]</p></td><td style="vertical-align:top"><p>36 (23.2%)</p><p>[16.8% ; 30.7%]</p></td><td style="vertical-align:top"><p>20.3%</p><p>[9.9% ; 30.8%]</p></td></tr><tr><td style="vertical-align:top"><p>Patients with confirmed CMV disease</p></td><td style="vertical-align:top"><p>60 (36.8%)</p><p>[29.4% ; 44.7%]</p></td><td style="vertical-align:top"><p>25 (16.1%)</p><p>[10.7% ; 22.9%]</p></td><td style="vertical-align:top"><p>20.7%</p><p>[10.9% ; 30.4%]</p></td></tr></tbody></table><p><sup>1 </sup>CMV Disease is defined as either CMV syndrome or tissue invasive CMV. <sup>2</sup> Confirmed CMV is a clinically confirmed case of CMV disease. Patients were assumed to have CMV disease if there was no week 52 assessment and no confirmation of CMV disease before this time point.</p><p><sup>A</sup> The results found up to 24 months were in line with the up to 12 month results: Confirmed or assumed CMV disease was 48.5% in the 100 days treatment arm versus 34.2% in the 200 days treatment arm; difference between the treatment groups was 14.3% [3.2 %; 25.3%].</p><p>Significantly less high risk kidney transplant patients developed CMV disease following CMV prophylaxis with Valganciclovir until Day 200 post-transplant compared to patients who received CMV prophylaxis with Valganciclovir until Day 100 post-transplant.</p><p>The graft survival rate as well as the incidence of biopsy proven acute rejection was similar in both treatment groups. The graft survival rate at 12 months post-transplant was 98.2 % (160/163) for the 100 day dosing regimen and 98.1 % (152/155) for the 200 day dosing regimen. Up to 24 month post-transplant, four additional cases of graft loss were reported, all in the 100 days dosing group. The incidence of biopsy proven acute rejection at 12 months post-transplant was 17.2% (28/163) for the 100 day dosing regimen and 11.0% (17/155) for the 200 day dosing regimen. Up to 24 month post-transplant, one additional case has been reported in the 200 days dosing group.</p><p>Viral resistance&nbsp;</p><p>Virus resistant to ganciclovir can arise after chronic dosing with valganciclovir by selection of mutations in the viral kinase gene (UL97) responsible for ganciclovir monophosphorylation and/or the viral polymerase gene (UL54). In clinical isolates, seven canonical UL97 substitutions, M460V/I, H520Q, C592G, A594V, L595S, C603W are the most frequently reported ganciclovir resistance-associated substitutions. Viruses containing mutations in the UL97 gene are resistant to ganciclovir alone, whereas viruses with mutations in the UL54 gene are resistant to ganciclovir but may show cross-resistance to other antivirals that also target the viral polymerase.</p><p><em>Treatment of CMV retinitis:</em>&nbsp;</p><p>Genotypic analysis of CMV in polymorphonuclear leucocytes (PMNL) isolates from 148 patients with CMV retinitis enrolled in one clinical study has shown that 2.2 %, 6.5 %, 12.8 %, and 15.3 % contain UL97 mutations after 3, 6, 12 and 18 months, respectively, of valganciclovir treatment.&nbsp;</p><p><em>Prevention of CMV disease in transplantation:</em>&nbsp;</p><p>Active comparator study&nbsp;</p><p>Resistance was studied by genotypic analysis of CMV in PMNL samples collected i) on Day 100 (end of study drug prophylaxis) and ii) in cases of suspected CMV disease up to 6 months after transplantation. From the 245 patients randomised to receive valganciclovir, 198 Day 100 samples were available for testing and no ganciclovir resistance mutations were observed. This compares with 2 ganciclovir resistance mutations detected in the 103 samples tested (1.9 %) for patients in the oral ganciclovir comparator arm.</p><p>Of the 245 patients randomised to receive valganciclovir, samples from 50 patients with suspected CMV disease were tested and no resistance mutations were observed. Of the 127 patients randomised on the ganciclovir comparator arm, samples from 29 patients with suspected CMV disease were tested, from which two resistance mutations were observed, giving an incidence of resistance of 6.9 %.</p><p>Extending prophylaxis study from 100 to 200 days post-transplant&nbsp;</p><p>Genotypic analysis was performed on the UL54 and UL97 genes derived from virus extracted from 72 patients who met the resistance analysis criteria: patients who experienced a positive viral load (&gt; 600 copies/ml) at the end of prophylaxis and/or patients who had confirmed CMV disease up to 12 months (52 weeks) post-transplant. Three patients in each treatment group had a known ganciclovir resistance mutation.</p><p>Paediatric population&nbsp;</p><p><em>Treatment of CMV retinitis:</em>&nbsp;</p><p>The European Medicines Agency has waived the obligation to perform studies with Valganciclovir in all subsets of the paediatric population in the treatment of infection due to CMV in immuno-compromised patients (see section 4.2 for information on paediatric use).</p><p>Prevention of CMV disease in transplantation&nbsp;</p><p>A phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged 4 months to 16 years, n = 63) receiving valganciclovir once daily for up to 100 days according to the paediatric dosing algorithm (see section 4.2) produced exposures similar to that in adults (see section 5.2). Follow up after treatment was 12 weeks. CMV D/R serology status at baseline was D+/R- in 40%, D+/R+ in 38%, D-/R+ in 19% and D-/R- in 3% of the cases. Presence of CMV virus was reported in 7 patients. The observed adverse drug reactions were of similar nature as those in adults (see section 4.8).</p><p>A phase IV tolerability study in paediatric kidney transplant recipients (aged 1 to 16 years, n=57) receiving valganciclovir once daily for up to 200 days according to the dosing algorithm (see section 4.2) resulted in a low incidence of CMV. Follow up after treatment was 24 weeks. CMV D/R serology status at baseline was D+/R+ in 45%, D+/R- in 39%, D-/R+ in 7%, D-/R- in 7% and ND/R+ in 2% of the cases. CMV viremia was reported in 3 patients and a case of CMV syndrome was suspected in one patient but not confirmed by CMV PCR by the central laboratory. The observed adverse drug reactions were of similar nature to those in adults (see section 4.8).</p><p>These data support the extrapolation of efficacy data from adults to children and provide posology recommendations for paediatric patients.&nbsp;</p><p>A phase I pharmacokinetic and safety study in heart transplant patients (aged 3 weeks to 125 days, n=14) who received a single daily dose of valganciclovir according to the paediatric dosing algorithm (see section 4.2) on 2 consecutive days produced exposures similar to those in adults (see section 5.2). Follow up after treatment was 7 days. The safety profile was consistent with other paediatric and adult studies, although patient numbers and valganciclovir exposure were limited in this study.</p><p>Congenital CMV&nbsp;</p><p>The efficacy and safety of ganciclovir and/or valganciclovir was studied in neonates and infants with congenital symptomatic CMV infection in two studies.</p><p>In the first study, the pharmacokinetics and safety of a single dose of valganciclovir (dose range 14-16-20 mg/kg/dose) was studied in 24 neonates (aged 8 to 34 days) with symptomatic congenital CMV disease (see section 5.2). The neonates received 6 weeks of antiviral treatment, whereas 19 of the 24 patients received up to 4 weeks of treatment with oral valganciclovir, in the remaining 2 weeks they received i.v. ganciclovir. The 5 remaining patients received i.v.</p><p>ganciclovir for the most time of the study period. In the second study the efficacy and safety of six weeks versus six months of valganciclovir treatment was studied in 109 infants aged 2 to 30 days with symptomatic congenital CMV disease. All infants received oral valganciclovir at a dose of 16 mg/kg b.i.d. for 6 weeks. After 6 weeks of treatment the infants were randomized 1:1 to continue treatment with valganciclovir at the same dose or receive a matched placebo to complete 6 months of treatment.</p><p>This treatment indication is not currently recommended for valganciclovir. The design of the studies and results obtained are too limited to allow appropriate efficacy and safety conclusions on valganciclovir.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of valganciclovir have been evaluated in HIV- and CMVseropositive patients, patients with AIDS and CMV retinitis and in solid organ transplant patients.</p><p>Dose proportionality with respect to ganciclovir AUC following administration of valganciclovir in the dose range 450 to 2625 mg was demonstrated only under fed conditions.</p><p>Absorption&nbsp;</p><p>Valganciclovir is a prodrug of ganciclovir. It is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Systemic exposure to valganciclovir is transient and low. The bioavailability of ganciclovir from oral dosing of valganciclovir is approximately 60 % across all the patient populations studied and the resultant exposure to ganciclovir is similar to that after its intravenous administration (please see below). For comparison, the bioavailability of ganciclovir after administration of 1000 mg oral ganciclovir (as capsules) is 6 - 8 %.<strong><em> </em></strong>&nbsp;</p><p><em>Valganciclovir in HIV positive, CMV positive patients:</em>&nbsp;</p><p>Systemic exposure of HIV positive, CMV positive patients after twice daily administration of ganciclovir and valganciclovir for one week is:</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td rowspan="2" style="vertical-align:top"><p>Ganciclovir (5 mg/kg,</p><p>i.v.)</p><p>n = 18</p></td><td colspan="2" style="vertical-align:top"><p>Valganciclovir (900 mg, p.o.)</p><p>n = 25</p></td></tr><tr><td style="vertical-align:top"><p>Ganciclovir</p></td><td style="vertical-align:top"><p>Valganciclovir</p></td></tr><tr><td style="vertical-align:top"><p>AUC(0 - 12 h) (&mu;g.h/ml)</p></td><td style="vertical-align:top"><p>28.6 &plusmn; 9.0</p></td><td style="vertical-align:top"><p>32.8 &plusmn; 10.1</p></td><td style="vertical-align:top"><p>0.37 &plusmn; 0.22</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (&mu;g/ml)</p></td><td style="vertical-align:top"><p>10.4 &plusmn; 4.9</p></td><td style="vertical-align:top"><p>6.7 &plusmn; 2.1</p></td><td style="vertical-align:top"><p>0.18 &plusmn; 0.06</p></td></tr></tbody></table><p>The efficacy of ganciclovir in increasing the time-to-progression of CMV retinitis has been shown to correlate with systemic exposure (AUC).</p><p><em>Valganciclovir in solid organ transplant patients:</em>&nbsp;</p><p>Steady state systemic exposure of solid organ transplant patients to ganciclovir after daily oral administration of ganciclovir and valganciclovir is:</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td rowspan="2" style="vertical-align:top"><p>Ganciclovir (1000 mg</p><p>t.i.d.)</p><p>n = 82</p></td><td style="vertical-align:top"><p>Valganciclovir (900 mg, od)</p><p>n = 161</p></td></tr><tr><td style="vertical-align:top"><p>Ganciclovir</p></td></tr><tr><td style="vertical-align:top"><p>AUC(0 - 24 h) (&mu;g.h/ml)</p></td><td style="vertical-align:top"><p>28.0 &plusmn; 10.9</p></td><td style="vertical-align:top"><p>46.3 &plusmn; 15.2</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (&mu;g/ml)</p></td><td style="vertical-align:top"><p>1.4 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>5.3 &plusmn; 1.5</p></td></tr></tbody></table><p>The systemic exposure of ganciclovir to heart, kidney and liver transplant recipients was similar after oral administration of valganciclovir according to the renal function dosing algorithm.</p><p><em>Food effect:</em>&nbsp;</p><p>When valganciclovir was given with food at the recommended dose of 900 mg, higher values were seen in both mean ganciclovir AUC (approximately 30 %) and mean ganciclovir C<sub>max</sub> values (approximately 14 %) than in the fasting state. Also, the inter-individual variation in exposure of ganciclovir decreases when taking Valganciclovir with food. Valganciclovir has only been administered with food in clinical studies. Therefore, it is recommended that Valganciclovir be administered with food (see section 4.2).</p><p><u>Distribution:</u>&nbsp;</p><p>Because of rapid conversion of valganciclovir to ganciclovir, protein binding of valganciclovir was not determined. The steady state volume of distribution (V<sub>d</sub>) of ganciclovir after intravenous administration was 0.680 &plusmn; 0.161 l/kg (n=114). For IV ganciclovir, the volume of distribution is correlated with body weight with values for the steady state volume of distribution ranging from</p><p>0.54-0.87 L/kg. Ganciclovir penetrates the cerebrospinal fluid. Binding to plasma proteins was 1%-2% over ganciclovir concentrations of 0.5 and 51 &micro;g/mL.</p><p>Biotransformation&nbsp;</p><p>Valganciclovir is rapidly and extensively metabolised to ganciclovir; no other metabolites have been detected. Ganciclovir itself is not metabolised to a significant extent.</p><p>Elimination&nbsp;</p><p>Following dosing with oral valganciclovir, the drug is rapidly hydrolysed to ganciclovir.</p><p>Ganciclovir is eliminated from the systemic circulation by glomerular filtration and active tubular secretion. In patients with normal renal function greater than 90% of IV administered ganciclovir was recovered un-metabolized in the urine within 24 hours. In patients with normal renal function the post-peak plasma concentrations of ganciclovir after administration of valganciclovir decline with a half-life ranging from 0.4 h to 2.0 h.</p><p>Pharmacokinetics in special clinical situations&nbsp;</p><p>Paediatric population&nbsp;</p><p>In a phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged 4 months to 16 years, n = 63) valganciclovir was given once daily for up to 100 days. Pharmacokinetic parameters were similar across organ type and age range and comparable with adults. Population pharmacokinetic modeling suggested that bioavailability was approximately 60%. Clearance was positively influenced by both body surface area and renal function.&nbsp;</p><p>In a phase I pharmacokinetic and safety study in paediatric heart transplant recipients (aged 3 weeks to 125 days, n = 14), valganciclovir was given once daily for two study days. Population pharmacokinetics estimated that mean bioavailability was 64%.&nbsp;</p><p>A comparison of the results from these two studies and the pharmacokinetic results from the adult population shows that ranges of AUC <sub>0-24h </sub>were very similar across all age groups, including adults. Mean values for AUC<sub>0-24h </sub>and C<sub>max</sub> were also similar across the paediatric age groups &lt; 12 years old, although there was a trend of decreasing mean values for AUC<sub>0-24h </sub>and C<sub>max</sub> across the entire pediatric age range, which appeared to correlate with increasing age. This trend was more apparent for mean values of clearance and half-life (t<sub>1/2</sub>); however this is to be expected as clearance is influenced by changes in weight, height and renal function associated with patient growth, as indicated by population pharmacokinetic modelling.&nbsp;</p><p>The following table summarizes the model-estimated AUC<sub>0-24h </sub>ranges for ganciclovir from these two studies, as well as mean and standard deviation values for AUC<sub>0-24h,</sub> C<sub>max</sub>, CL and t &frac12; for the relevant paediatric age groups compared to adult data:</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p><strong>PK Parameter</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Adults*</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Paediatrics</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&ge; 18 years</strong>&nbsp;</p><p><strong>(n=160)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&lt; 4 months </strong></p><p><strong>(n = 14)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>4 months - &le; 2 years </strong>&nbsp;</p><p><strong>(n=17)</strong></p></td><td style="vertical-align:top"><p><strong>&gt; 2 - &lt; 12 years</strong>&nbsp;</p><p><strong>(n=21)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&ge; 12 years &ndash; 16 years</strong>&nbsp;</p><p><strong>(n=25)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC</strong><strong>0-24h (&mu;g<sup>.</sup>h/ml)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>46.3 &plusmn; 15.2</p></td><td style="vertical-align:top"><p>68.1 &plusmn; 19.8</p></td><td style="vertical-align:top"><p>64.3 &plusmn; 29.2</p></td><td style="vertical-align:top"><p>59.2 &plusmn; 15.1</p></td><td style="vertical-align:top"><p>50.3 &plusmn; 15.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Range of AUC<sub>0-</sub></strong></p><p><strong>24h</strong>&nbsp;</p></td><td style="vertical-align:top"><p>15.4 &ndash; 116.1</p></td><td style="vertical-align:top"><p>34 - 124</p></td><td style="vertical-align:top"><p>34 - 152</p></td><td style="vertical-align:top"><p>36 - 108</p></td><td style="vertical-align:top"><p>22 - 93</p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>max</sub> (&mu;g/ml)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>5.3 &plusmn; 1.5</p></td><td style="vertical-align:top"><p>10.5 &plusmn; 3.36</p></td><td style="vertical-align:top"><p>10.3 &plusmn; 3.3</p></td><td style="vertical-align:top"><p>9.4 &plusmn; 2.7</p></td><td style="vertical-align:top"><p>8.0 &plusmn; 2.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clearance (l/h)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>12.7 &plusmn; 4.5</p></td><td style="vertical-align:top"><p>1.25 &plusmn; 0.473</p></td><td style="vertical-align:top"><p>2.5 &plusmn; 2.4</p></td><td style="vertical-align:top"><p>4.5 &plusmn; 2.9</p></td><td style="vertical-align:top"><p>6.4 &plusmn; 2.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>t<sub>1/2</sub> (h)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>6.5 &plusmn; 1.4</p></td><td style="vertical-align:top"><p>1.97 &plusmn; 0.185</p></td><td style="vertical-align:top"><p>3.1 &plusmn;1.4</p></td><td style="vertical-align:top"><p>4.1 &plusmn; 1.3</p></td><td style="vertical-align:top"><p>5.5 &plusmn; 1.1</p></td></tr></tbody></table><p>* Extracted from study report PV 16000</p><p>The once daily dose of Valganciclovir in both of the studies described above was based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and was calculated using the dosing algorithm presented in section 4.2.</p><p>Ganciclovir pharmacokinetics following valganciclovir administration were also evaluated in two studies in neonates and infants with symptomatic congenital CMV disease. In the first study 24 neonates aged 8 to 34 days received 6 mg/kg intravenous ganciclovir twice daily. Patients were then treated with oral valganciclovir, where the dose of valganciclovir powder for oral solution ranged from 14 mg/kg to 20 mg/kg twice daily; total treatment duration was 6 weeks. A dose of 16 mg/kg twice daily of valganciclovir powder for oral solution provided comparable ganciclovir exposure as 6 mg/kg intravenous ganciclovir twice daily in neonates, and also achieved ganciclovir exposure similar to the effective adult 5 mg/kg intravenous dose.&nbsp;</p><p>In the second study, 109 neonates aged 2 to 30 days received 16 mg/kg valganciclovir powder for oral solution twice daily for 6 weeks and subsequently 96 out of 109 enrolled patients were randomized to continue receiving valganciclovir or placebo for 6 months. However, the mean AUC<sub>0-12h</sub> was lower compared to the mean AUC<sub>0-12h</sub> values from the first study. The following table shows the mean values of AUC, C<sub>max</sub>, and t<sub>&frac12; </sub>including standard deviations compared with adult data:</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p><strong>PK Parameter</strong>&nbsp;</p></td><td style="vertical-align:top"><p>Adults</p></td><td colspan="3" style="vertical-align:top"><p>Paediatrics (neonates and infants)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>5 mg/kg GAN</strong></p><p><strong>Single dose</strong>&nbsp;</p><p><strong>(n=8)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>6 mg/kg GAN</strong>&nbsp;</p><p><strong>Twice daily</strong>&nbsp;</p><p><strong>(n=19)</strong></p></td><td style="vertical-align:top"><p><strong>16 mg/kg VAL</strong>&nbsp;</p><p><strong>Twice daily</strong>&nbsp;</p><p><strong>(n=19)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>16 mg/kg VAL</strong>&nbsp;</p><p><strong>Twice daily</strong>&nbsp;</p><p><strong>(n = 100)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC<sub>0-&infin;</sub> (&mu;g<sup>.</sup>h/mL)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>25.4 &plusmn; 4.32</p></td><td style="vertical-align:top"><p><strong>-</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC</strong><strong>0-12h (&mu;g</strong><strong>.h/mL)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>38.2 &plusmn; 42.7</p></td><td style="vertical-align:top"><p>30.1 &plusmn; 15.1</p></td><td style="vertical-align:top"><p>20.85 &plusmn; 5.40</p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>max</sub> (&mu;g/ml)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>9.03 &plusmn; 1.26</p></td><td style="vertical-align:top"><p>12.9 &plusmn; 21.5</p></td><td style="vertical-align:top"><p>5.44 &plusmn; 4. 04</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>t<sub>1/2</sub> (h)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>3.32 &plusmn; 0.47</p></td><td style="vertical-align:top"><p>2.52 &plusmn; 0. 55</p></td><td style="vertical-align:top"><p>2.98 &plusmn; 1. 26</p></td><td style="vertical-align:top"><p>2.98 &plusmn; 1.12</p></td></tr></tbody></table><p>GAN = Ganciclovir, i.v. VAL = Valganciclovir, oral&nbsp;</p><p>These data are too limited to allow conclusions regarding efficacy or posology recommendations for paediatric patients with congenital CMV infection.</p><p>Elderly</p><p>No investigations on valganciclovir or ganciclovir pharmacokinetics in adults older than 65 years of age have been undertaken (see section 4.2).</p><p>Patients with renal impairment</p><p>The pharmacokinetics of ganciclovir from a single oral dose of 900 mg valganciclovir was evaluated in 24 otherwise healthy individuals with renal impairment.</p><p>Pharmacokinetic parameters of ganciclovir from a single oral dose of 900 mg Valganciclovir tablets in patients with various degrees of renal impairment:</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td style="vertical-align:top"><p><strong>Estimated </strong></p><p><strong>Creatinine </strong></p><p><strong>Clearance </strong></p><p><strong>(mL/min)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Apparent Clearance </strong></p><p><strong>(mL/min) Mean </strong>&plusmn; <strong>SD </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>AUClast (&mu;g∙h/mL) Mean </strong>&plusmn; <strong>SD</strong></p></td><td style="vertical-align:top"><p><strong>Half-life (hours) Mean </strong>&plusmn;</p><p><strong>SD</strong></p></td></tr><tr><td style="vertical-align:top"><p>51-70&nbsp;</p></td><td style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>249 &plusmn; 99&nbsp;</p></td><td style="vertical-align:top"><p>49.5 &plusmn; 22.4&nbsp;</p></td><td style="vertical-align:top"><p>4.85 &plusmn; 1.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21-50&nbsp;</p></td><td style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>136 &plusmn; 64&nbsp;</p></td><td style="vertical-align:top"><p>91.9 &plusmn; 43.9&nbsp;</p></td><td style="vertical-align:top"><p>10.2 &plusmn; 4.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>11-20&nbsp;</p></td><td style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>45 &plusmn; 11&nbsp;</p></td><td style="vertical-align:top"><p>223 &plusmn; 46&nbsp;</p></td><td style="vertical-align:top"><p>21.8 &plusmn; 5.2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&le;10&nbsp;</p></td><td style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>12.8 &plusmn; 8&nbsp;</p></td><td style="vertical-align:top"><p>366 &plusmn; 66&nbsp;</p></td><td style="vertical-align:top"><p>67.5 &plusmn; 34&nbsp;</p></td></tr></tbody></table><p>Decreasing renal function resulted in decreased clearance of ganciclovir from valganciclovir with a corresponding increase in terminal half-life. Therefore, dosage adjustment is required for renally impaired patients (see sections 4.2 and 4.4).</p><p>Patients undergoing haemodialysis</p><p>For patients receiving haemodialysis dose recommendations for Valganciclovir 450 mg filmcoated tablets cannot be given. This is because an individual dose of Valganciclovir required for these patients is less than the 450 mg tablet strength. Thus, Valganciclovir film-coated tablets should not be used in these patients (see sections 4.2 and 4.4).</p><p>Stable liver transplant patients</p><p>The pharmacokinetics of ganciclovir from valganciclovir in stable liver transplant patients were investigated in one open label 4-part crossover study (N=28). The bioavailability of ganciclovir from valganciclovir, following a single dose of 900 mg valganciclovir under fed conditions, was approximately 60%. Ganciclovir AUC<sub>0-24h </sub>was comparable to that achieved by 5 mg/kg intravenous ganciclovir in liver transplant patients.</p><p>Patients with hepatic impairment</p><p>The safety and efficacy of Valganciclovir film-coated tablets have not been studied in patients with hepatic impairment. Hepatic impairment should not affect the pharmacokinetics of ganciclovir since it is excreted renally and, therefore, no specific dose recommendation is made.</p><p>Patients with cystic fibrosis</p><p>In a phase I pharmacokinetic study in lung transplant recipients with or without cystic fibrosis</p><p>(CF), 31 patients (16 CF/15 non-CF) received post-transplant prophylaxis with 900 mg/day Valganciclovir. The study indicated that cystic fibrosis had no statistically significant influence on the overall average systemic exposure to ganciclovir in lung transplant recipients. Ganciclovir exposure in lung transplant recipients was comparable to that shown to be efficacious in the prevention of CMV disease in other solid organ transplant recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valganciclovir is a pro-drug of ganciclovir and therefore effects observed with ganciclovir apply equally to valganciclovir. Toxicity of valganciclovir in pre-clinical safety studies was the same as that seen with ganciclovir and was induced at ganciclovir exposure levels comparable to, or lower than, those in humans given the induction dose.</p><p>These findings were gonad toxicity (testicular cell loss) and nephrotoxicity (uraemia, cell degeneration), which were irreversible; myelotoxicity (anaemia, neutropenia, lymphocytopenia) and gastrointestinal toxicity (mucosal cell necrosis), which were reversible.</p><p>Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. Such results are consistent with the positive mouse carcinogenicity study with ganciclovir. Ganciclovir is a potential carcinogen.</p><p>Further studies have shown ganciclovir to be teratogenic, embryotoxic, to inhibit spermatogenesis (i.e. impair male fertility) and to suppress female fertility.</p><p>Animal data indicate that ganciclovir is excreted in the milk of lactating rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valganciclovir Tablets 450mg</p><p>&nbsp;The other ingredients are: cellulose microcrystalline, Crospovidone, Povidone, Stearic Acid, Purified Water</p><p>Film Coating Composition: HPMC 2910 Hypromellose Titanium Dioxide, Yellow Iron Oxide,</p><p>Iron Oxide red, -Talc <strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6&nbsp; X 10&rsquo;s Alu-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Saudi Hetero Lab Ltd. 
   Aljameah Street, Malaz quarter,  
    Riyadh 11441, Saudi Arabia 
    Tel: +966 11 477 2215 
    Manufacture: 
    Hetero Lab Limited Unit V, Hyderabad, India. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>